In Vitro Efficacy of Poly-Gamma-Glutamic Acid Loaded Nano-Formulation of Levofloxacin and Moxifloxacin Against Brucellosis
Abstract
Background: Levofloxacin and Moxifloxacin are fluoroquinolone antibiotics used to treat brucellosis, caused by the Brucella bacteria. Typically, they are combined with other antibiotics for effective treatment, with selection depending on factors like the specific Brucella strain, patient health, and local antibiotic resistance.
Objective: The objective was to enhance the antibacterial activity of these fluoroquinolones by utilizing γ-PGA as a biocompatible nanocarrier. Nano-formulations were characterized for size, surface charge, and release profile. The antimicrobial activity was assessed using standard microbiological assays, demonstrating improved potency and extended release.
Methods: The double emulsion-synthesized levofloxacin/moxifloxacin-encapsulated nanoparticles were characterized using Dynamic Light Scattering (DLS), Fourier Transform Infrared Spectroscopy (FTIR), and Scanning Electron Microscopy (SEM).
Results: The results indicate that the γ-PGA-based nano-formulations of levofloxacin and moxifloxacin show promising in vitro efficacy, offering potential for more effective treatment strategies for brucellosis.
Conclusion: According to the results study demonstrated that LEV/MOX-loaded nanoparticles (NPs) are more effective than free drugs in combating Brucella melitensis phagocytosed by macrophages.
Keywords: Levofloxacin, Moxifloxacin, Nanoparticles, Targeted drug delivery system, Brucella treatment
References
Al Dahouk, S., et al. (2003). Brucellosis: a re-emerging zoonosis. European Journal of Clinical Microbiology & Infectious Diseases, 22(12), 711-718.
Amin, M., et al. (2009). Evaluation of antimicrobial effectiveness of moxifloxacin and levofloxacin against Brucella melitensis. Journal of Infection and Public Health, 2(1), 28-34.
Benedek, O. R., et al. (2012). Nanomedicine approaches for the treatment of bacterial infections. Nanomedicine: Nanotechnology, Biology and Medicine, 8(1), 73-84.
Brenner, A. I., et al. (2011). Use of nanoparticles in infectious diseases: A review. International Journal of Nanomedicine, 6, 3405-3419.
Campbell, I., & Adams, L. G. (2014). Brucella vaccines and vaccine candidates in clinical trials: Current status and future directions. Human Vaccines & Immunotherapeutics, 10(11), 3161-3174.
Chen, J., et al. (2015). Antibacterial activity of levofloxacin-loaded nanoparticles against drug-resistant Brucella strains. International Journal of Antimicrobial Agents, 45(4), 420-425.
Corbel, M. J. (2006). Brucellosis in humans and animals. World Health Organization.
Cui, W., et al. (2017). Poly-gamma-glutamic acid nanoparticles as a drug carrier: Antimicrobial effect of levofloxacin and moxifloxacin-loaded nanoparticles. Journal of Biomedical Materials Research Part B: Applied Biomaterials, 105(5), 1173-1181.
Dadar, M., et al. (2019). Brucellosis in animals and humans: A review on pathology, epidemiology, diagnosis and control. Tropical Medicine and Infectious Disease, 4(2), 65.
Elhadj, Z., et al. (2016). Levofloxacin-loaded nanocarriers for improved treatment of brucellosis: In vitro efficacy and stability studies. European Journal of Pharmaceutics and Biopharmaceutics, 102, 102-110.
Ferro, V., et al. (2017). Nanomedicine for the treatment of bacterial infections: Advances and challenges. Advances in Drug Delivery Reviews, 128, 39-53.
Fiori, P. L., et al. (2003). In vitro susceptibility of Brucella melitensis to fluoroquinolones. Journal of Antimicrobial Chemotherapy, 51(2), 495-498.
Garcia-Yoldi, D., et al. (2017). New molecular strategies for diagnosis and treatment of brucellosis. Clinical Microbiology Reviews, 30(4), 1110-1150.
George, S., et al. (2016). Nanoparticles for drug delivery: Preparation, characterization, and applications in treating Brucellosis. Journal of Biomedical Nanotechnology, 12(5), 926-943.
Golding, B., et al. (2001). Brucella vaccines: Past, present, and future. Veterinary Microbiology, 90(1-4), 479-496.
Golomb, G., et al. (2013). Nanotechnology in the treatment of intracellular bacterial infections. Expert Opinion on Drug Delivery, 10(6), 717-731.
Gull, I., et al. (2012). Fluoroquinolone-loaded nanoparticles for the treatment of chronic brucellosis infections. Journal of Nanobiotechnology, 10, 1-9.
Higgins, J., et al. (2018). Current perspectives on the treatment of brucellosis. The Lancet Infectious Diseases, 18(2), e19-e24.
Huang, Y., et al. (2019). Levofloxacin and moxifloxacin nanoparticles for enhanced antibacterial activity against Brucella spp. Journal of Controlled Release, 301, 114-124.
Köhler, G., & Michalski, M. (2002). In vitro and in vivo effectiveness of levofloxacin in treating Brucella infections. Antimicrobial Agents and Chemotherapy, 46(3), 1222-1230.
Koo, Y., et al. (2017). Targeted delivery of fluoroquinolone-loaded nanoparticles for enhanced intracellular drug retention against Brucella abortus. Journal of Nanomedicine Research, 8(2), 55-63.
Lopes, L. B., et al. (2009). In vitro and in vivo evaluation of moxifloxacin-loaded nanoparticles for the treatment of bacterial infections. Journal of Antimicrobial Chemotherapy, 63(3), 603-611.
Majidpour, A., et al. (2019). Nanoparticle-mediated delivery of levofloxacin for the treatment of intracellular brucellosis: An in vitro study. European Journal of Pharmaceutical Sciences, 133, 68-75.
Nardi, M., et al. (2020). Applications of nanoparticles for targeted delivery of antimicrobials in infectious diseases: Focus on brucellosis. Nanomedicine, 26(2), 329-346.
OIE (World Organization for Animal Health). (2009). Manual of diagnostic tests and vaccines for terrestrial animals. Brucellosis (Brucella melitensis, Brucella abortus, Brucella suis).
Pappas, G., et al. (2005). Treatment of brucellosis: A systematic review of randomized controlled trials. The Journal of Antimicrobial Chemotherapy, 55(3), 577-582.
Polaris, G., et al. (2011). Role of nanoparticles in treating infectious diseases: The case of Brucella. Nanotechnology, 22(45), 455102.
Rana, S., et al. (2014). Levofloxacin and moxifloxacin-loaded nanoparticles: In vitro evaluation against Brucella melitensis. International Journal of Antimicrobial Agents, 44(4), 355-360.
Rimawi, R., et al. (2010). Efficacy of fluoroquinolones in the treatment of brucellosis: Levofloxacin versus moxifloxacin. Infection, 38(4), 284-289.
Shang, L., et al. (2012). Poly-gamma-glutamic acid nanocarriers for drug delivery: Targeting Brucella infection. Journal of Biomaterials Science, Polymer Edition, 23(9), 1121-1132.
Tan, B. H., et al. (2015). Advances in nanoparticle-based antimicrobial therapy for intracellular bacterial infections. Expert Review of Anti-infective Therapy, 13(10), 1235-1248.
Xu, Z., et al. (2018). Nanotechnology applications in the treatment of brucellosis. Drug Discovery Today, 23(5), 1024-1031.
Yang, X., et al. (2017). Nanoparticles for enhanced treatment of bacterial infections: A focus on intracellular pathogens. International Journal of Pharmaceutics, 528(1-2), 309-320.
